Lerong Li

发表

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Pan Tong, John V Heymach, Abena B. Redwood, 2017, Cancer research.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

Ying Feng, Pan Tong, Robert J. Cardnell, 2017, Oncotarget.